Nandhini Subramaniam, Arvind Muthukrishnan
Dr. Nandhini Subramaniam1*, Dr. Arvind Muthukrishnan2
1Senior Lecturer, Department of Oral Medicine and Radiology, Saveetha Dental College and Hospitals, SIMATS, Chennai, India.
2Professor and Head (Academics), Department of Oral Medicine and Radiology, Saveetha Dental College and Hospitals, SIMATS, Chennai, India.
Volume - 14,
Issue - 9,
Year - 2021
Introduction: Bone antiresorptive drugs are commonly prescribed for osteoporosis, Paget's disease, multiple myeloma, metastasis-associated with breast/prostate cancer. The most common complication of these drugs is the risk of developing osteonecrosis of the jaw. Maximum precautions should be taken in these patients before undertaking invasive dental procedures as they are at risk of developing osteonecrosis of the jaw. Thus, the purpose of this study is to assess the knowledge and practice among the dental practitioners in managing patients on these group of drugs. Aim: To assess the knowledge and practice regarding the management of patients under bone anti-resorptive therapy among dental practitioners in Saveetha Dental College. Materials and methods: A cross-sectional survey was conducted using a self-prepared and pre-validated questionnaire containing 13 close-ended questions on knowledge and practice among 150 dental practitioners in Saveetha Dental College. Results: Out of 150 Dental practitioners, 69% were female and 31% were male. About 33% of dentists had more than 2 years of experience while 67% had less than 2 years of experience. Qualification distribution revealed 50.7% of dental specialists and 49.3% dental graduates. The mean score of Knowledge and practice was high among males when compared to females, high among dental specialists with more than 2 years of experience. Conclusion: The practitioners are aware of the antiresorptive group of drugs, its indication, and oral complication. The management protocol, precautions needed to treat these patients for any invasive dental procedures are well understood by the Dental practitioners.
Cite this article:
Nandhini Subramaniam, Arvind Muthukrishnan. Management of patients under Bone Anti-Resorptive Drugs- A Survey among Dental Practitioners. Research Journal of Pharmacy and Technology. 2021; 14(9):5003-6. doi: 10.52711/0974-360X.2021.00871
Nandhini Subramaniam, Arvind Muthukrishnan. Management of patients under Bone Anti-Resorptive Drugs- A Survey among Dental Practitioners. Research Journal of Pharmacy and Technology. 2021; 14(9):5003-6. doi: 10.52711/0974-360X.2021.00871 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-9-85
1. Henneman ZJ, Nancollas GH, Ebetino FH, Russell RGG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A. 2008; 85A (4): 993-1000.
2. Salvatore L. Ruggiero, Thomas B. Dodson, John Fantasia, Reginald Goodday, Tara Aghaloo, Mehrotra B, et al. Medication-Related Osteonecrosis of the Jaw-2014 Update.
3. Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011; 48(4): 677-92.
4. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19(6): 733-59.
5. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw [ONJ] after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2008; 20(1): 117-20.
6. Allen MR, Burr DB. The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data. J Oral Maxillofac Surg. 2009; 67(5): 61-70.
7. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw: Landesberg et al. Ann N Y Acad Sci. 2011; 1218(1): 62-79.
8. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18(2): 75-85.
9. Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, et al. Bisphosphonates Cause Osteonecrosis of the Jaw-Like Disease in Mice. Am J Pathol. 2010; 177(1): 280-90.
10. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular Mechanisms of Action of Bisphosphonates: Current Status. Clin Cancer Res. 2006; 12(20): 6222s-6230s.
11. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Breast Cancer Res Treat. 2009; 116(3): 433-9.
12. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw [ONJ] during adjuvant therapy in a randomized phase III trial [AZURE: BIG 01–04] for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011; 127(2): 429-38.
13. Malden N, Lopes V: An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2012; 30: 171-174.
14. Shannon J, Shannon J, Modelevsky S, et al: Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc. 2011; 59: 2350-2356.
15. Marx RE, Cillo JE, Jr., Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65: 2397-2402.
16. Saussez S, Javadian R, Hupin C, et al: Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope. 2009; 119: 323-327.
17. Fedele S, Porter SR, D'Aiuto F, et al: Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010; 123: 1060-1064.
18. O'Ryan FS, Khoury S, Liao W, et al: Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009; 67: 1363-1369.
19. Bedogni A, Fusco V, Agrillo A, et al: Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw [BRONJ]. Oral Dis. 2012; 18: 621-624.
20. Kumar SK, Gorur A, Schaudinn C, et al: The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep. 2010; 8: 40-44.